Progress of increasing research in stem cell & tissue production technology as well as changes of treatment process towards personalized medicine, made some researchers in stem cell & tissue production field to think up regarding production of stem cell & tissue for therapeutic & research uses in sterile and suitable environment as the first time in Iran and providing associated commercialization trends. For this purpose, SinaCell as a research and manufacturer company has been established in 1386, began its carrier with universities approved research projects in the field of stem cell treatment. Afterward, company signed technology procurement contract with Germany in the field of tissue production to treat damaged cartilage of the knee, in addition to signing a contract with Austria for training staff to produce cartilage, subsequently, cartilage production technology has been implemented in company.
SinaCell is the first company who achieved Ministry of Health GMP (Good Manufacturing Product) confirmation to produce stem cell, cartilage, amniotic membrane, fat cells and Platelet-rich plasma.
One of the SinaCell priorities is to meet the demand of patients in need of stem cells to cure them. It can be applicable upon permission of Ministry of Health. However, the company continues its cooperation with universities and scientific centers to carry out research projects in the field of stem cells and tissue.
Knowledge-based SinaCell company future perspective is becoming to the manufacturing pole based on regenerative medicine products in the region. Accordingly, using modern technology and relying on company staff scientific background in manufacturing new products based on regenerative medicine, we move to find new therapies for incurable diseases.
SinaCell mission is to create reliable and efficient bridge between regenerative medicine products in laboratory stage and pre-clinical stage up to therapy stage. In this regard, the company’s research and development unit is dealing with to find reliable cell sources and study safety and efficiency of the cell products. The production unit also comply with international standards based on regulations passed by GMP is trying to produce safe and efficient products. Quality Assurance Unit also closely monitoring all stages of production from beginning to end, according to the defined protocols in compliance with international standards.
Our Strategic Goals
– Become the regional hub in production of regenerative medicine-based products.
– Development of new therapies for incurable diseases in the country.
– Production of cell-based products in the field of orthopedic diseases, cardiovascular, skin, neurodegenerative and autoimmune diseases, urology, nephrology and Hepatic Gastrointestinal.
– Codification of accurate and reliable standards for production and quality assurance of regenerative medicine-based products.
– Export regenerative medicine-based products to the countries in region in order to strengthen the knowledge-based economy.